Skip to content

Author

M. Machaalani

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...

É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al. · 0 citations
Open access Sep 2026

14 Evaluation of the Effects of the HIF-2α Inhibitor Belzutifan on T-cell–Mediated Cytotoxicity in Renal Cell Carcinoma

Abstract Background Renal cell carcinoma (RCC) is characterized by a hypoxic tumor microenvironment that recruits immunosuppressive macrophages and regulatory T cells to suppress anti-tumor immunity. Belzutifan, a hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor recently approved by the FDA, significantly improves p...

S. Kashima, Katrine N. Madsen, H. Soulati et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.